Interim report 2026
Filed with HKEX · Stock code 2637 · · 81 pages · English
Fujian Haixi Pharmaceuticals Co., Ltd. (“Haixi Pharmaceuticals” or the “Company”, together with its subsidiaries, the “Group”) was established in the People’s Republic of China (the “PRC”) as a limited liability company on 27 March 2012 and was converted into a joint stock company with limited liability on 15 November 2022 under laws of the PRC. It is a commercialstage innovative pharmaceutical co
Fujian Haixi Pharmaceuticals Co., Ltd. on 6ix
Earlier from Fujian Haixi Pharmaceuticals
- Voluntary announcement - HX9428 latest data from Phase I and Phase II clinical studies for the treatment of neovascular age-related macular degeneration (nAMD)
- Fujian Haixi Pharmaceuticals Says US FDA Approves IND Application Of HX9428
- Fujian Haixi Pharmaceuticals Nominates Chen Tingze As Candidate For Executive Director
Later from Fujian Haixi Pharmaceuticals
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - progress update on purchases of h shares pursuant to the share incentive scheme
Follow Fujian Haixi Pharmaceuticals into a list and get an email when it puts out news.
Follow Fujian Haixi Pharmaceuticals